Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: BPJS sejak berdiri tahun 2014 sampai saat ini berusaha menerapkan pelayanan yang setara. Kesenjangan pelayanan dalam segi fasilitas kesehatan di seluruh Rumah Sakit di Indonesa menjadi permasalahan yang tak kunjung usai sehingga terbitlah peraturan pemerintah No 47 tahun 2021 tentang KRIS-JKN. Hadir dengan 12 kriterianya untuk menjawab tantangan ketidaksetaraan pada fasilitas salah satunya RS Yarsi. Dilakukan uji coba penerapan tahun 2022 oleh DJSN didapati bahwa 79% RS membutuhkan perbaikan infrastruktur dalam skala kecil, 18% RS perlu perbaikan skala besar, dan 3% RS dinyatakan sudah siap. Peraturan Presiden No 59 tahun 2024 mewajibkan seluruh rumah sakit siap menerapkan KRIS-JKN paling lambat 30 Juni 2025.Tujuan penelitian: Mengetahui kesiapan penerapan dan mengusulkan strategi penyiapan KRIS-JKN di RS Yarsi.Metodologi penelitian: Menggunakan pendekatan kualitatif dengan desain action research menggunakan data primer temuan di lapangan dan data sekunder (file-file di rumah sakit) dan hasil wawancara. Penelitian ini dilaksanakan dari bulan April hingga Mei 2024.Hasil penelitian: Didapatkan hasil bahwa RS Yarsi sudah 80 % siap untuk menerapkan KRIS-JKN. Beberapa hal yang menjadi faktor internal dan faktor eksternal setelah melewati diskusi dengan tim CDMG kemudian dimasukan ke  matrix IE, penerapan KRIS-JKN di RS Yarsi berada di posisi sel 1, build and grow. Di matrix TOWS strategi yang diusulkan, yaitu Product Development dan Market Development. Pada tahapan penyusunan strategi pada matrix TOWS didapati prioritas pertama adalah pengembangan sarana dan prasarana, yaitu Pengganggaran revitalisasi sarana dan prasarana, optimalisasi SIMRS, penyesuaian kebutuhan sarana sesuai kriteria KRIS-JKN. Prioritas kedua pengembangan kompetensi SDM, yaitu dengan recruitement SDM yang kompeten dan kepala instalansi rawat inap, melakukan refreshement dan bounding antar pegawai. Prioritas ketiga pengembangan segmen pasar, yaitu melalui promosi layanan unggulan dan penguatan kerjasama lintas sektor, perbaikan manajemen tempat tidur RS, Customer Relationship Management (CRM), dan peningkatan enggangement dengan pelanggan dan mitra.Kesimpulan: RS Yarsi 80 % siap dalam menerapkan KRIS-JKN dengan strategi penyiapan yang diusulkan adalah Product Development dan Market Development dengan prioritas strategi pertama yaiitu pengembangan saran dan prasarana, kedua pengembangan kompetensi SDM, dan ketiga pengembangan segmen pasar.

---

Background:  BPJS since its establishment in 2014 until now has tried to implement equal services. The gap in services in terms of health facilities in all hospitals in Indonesia has become a never-ending problem so that government regulation No. 47 of 2021 concerning KRIS-JKN was issued. It comes with 12 criteria to answer the challenge of inequality in facilities, one of which is Yarsi Hospital. A trial implementation in 2022 by DJSN found that 79% of hospitals needed small-scale infrastructure improvements, 18% of hospitals needed large-scale repairs, and 3% of hospitals were declared ready. Presidential Regulation No. 59 of 2024 requires all hospitals to be ready to implement KRIS-JKN no later than June 30, 2025.

Objective: Knowing the readiness of implementation and proposing a strategy for the preparation of KRIS-JKN at Yarsi Hospital.

Methode: Using a qualitative approach with an action research design using primary data from findings in the field and secondary data (files in hospitals) and interview results. This research was carried out from April to May 2024.

Results: The results were obtained that Yarsi Hospital is 80% ready to implement KRIS-JKN. Several things that became internal factors and external factors after going through discussions with the CDMG team were then included in the IE matrix, the implementation of KRIS-JKN at Yarsi Hospital was in the position of cell 1, build and grow. In the TOWS matrix, the proposed strategies are Product and Market Development. At the stage of strategy preparation in the TOWS matrix, it was found that the first priority was the development of facilities and infrastructure, namely the revitalization of facilities and infrastructure, optimization of SIMRS, adjustment of facility needs according to KRIS-JKN criteria. The second priority is the development of human resource competencies, namely by recruiting competent human resources and heads of inpatient installations, conducting refreshements and bounding between employees. The third priority for market segment development is through the promotion of superior services and strengthening cross-sector cooperation, improving hospital bed management, Customer Relationship Management (CRM), and improving engagement with customers and partners.

Conclusion: RS Yarsi is 80% ready to implement KRIS-JKN with the proposed preparation strategy of Product Development and Market Development with the first strategic priority, namely the development of advice and infrastructure, the second is the development of human resource competencies, and the third is the development of market segments."

"Sindrom koroner akut (SKA) merupakan masalah kesehatan nasional karena tingginya angka morbiditas dan mortalitas serta beban biaya yang dibutuhkan. Intervensi koroner perkutan (IKP) dan terapi antiplatelet seperti klopidogrel merupakan tata laksana yang direkomendasikan oleh organisasi kardiologi internasional. Meskipun demikian, pasien SKA masih dapat mengalami kejadian kardiovaskular mayor (KKM). Kemungkinan, resistensi klopidogrel berperan pada KKM sedangkan resistensi klopidogrel mungkin dipengaruhi oleh faktor genetik dan epigenetik. Penelitian ini bertujuan untuk mengetahui hubungan faktor genetik yaitu polimorfisme gen CYP2C19 dan P2Y12, serta epigenetik yaitu metilasi DNA gen CYP2C19 dan P2Y12 serta ekspresi miRNA-26a dengan resistensi klopidogrel dan pengaruhnya terhadap KKM pada pasien SKA pasca IKP.Untuk menganalisis hubungan faktor genetik dan epigenetik dengan resistensi klopidogrel, penelitian dilakukan dengan desain potong lintang, sedangkan untuk analisis hubungan faktor genetik dan epigenetik dengan KKM dilakukan dengan desain kohort prospektif. Subjek penelitian meliputi 201 pasien SKA pasca IKP dan mendapat terapi klopidogrel di Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita dari bulan September 2018 sampai dengan Juni 2020. Resistensi klopidogrel ditentukan dengan pemeriksaan light transmission aggregometry (LTA) apabila hasilnya lebih besar dari 59% dengan agonis ADP 20 mM. Deteksi polimorfisme gen CYP2C19 dan P2Y12 serta ekspresi miRNA-26a dilakukan dengan metode qRT-PCR, sedangkan metilasi DNA gen CYP2C19 dan P2Y12 dikerjakan dengan metode konversi bisulfit. Pasien diobservasi selama satu tahun dan jika ada angina pektoris, infark miokard akut (IMA) rekuren, stroke, atau kematian, dicatat sebagai KKM.Dari 201 subjek, terdapat 45,8% carrier mutant polimorfisme *2 dan *3 gen CYP2C19, 36,8% carrier mutant polimorfisme rs3679479 gen P2Y12, 10% hipometilasi DNA gen P2Y12, 80,1% hipometilasi DNA gen CYP2C19, dan 66,2% ekspresi miRNA-26a up regulated. Proporsi resisten klopidogrel adalah 49,8% dan proporsi KKM adalah 14,9% (kematian 7,5%). Terdapat hubungan antara merokok (p = 0,001; OR 0,37 [IK 95%; 0,20–0,68]), hipometilasi DNA gen CYP2C19 (p = 0,037; OR 2,13 [IK 95%; 1,04–4,37]), dan ekspresi miRNA-26a up regulated (p = 0,020; OR 2,03 [IK 95%; 1,12–3,68]) dengan resistensi klopidogrel. Terdapat hubungan antara jenis kelamin perempuan (p = 0,040; HR 2,73 [IK 95%; 1,05–7,14]), usia ≥ 60 tahun (p = 0,035; HR 2,17 [IK 95%; 1,06–4,48]), eGFR rendah (p = 0,001; HR 3,29 [IK 95%; 1,59–6,84]), dan polimorfisme *2 dan *3 gen CYP2C19 (p = 0,047; HR 2,12 [IK 95%; 1,01–4,46]) dengan KKM dalam satu tahun.Hanya faktor epigenetik berupa metilasi DNA gen CYP2C19 dan ekspresi miRNA-26a yang berhubungan dengan resistensi klopidogrel. Walaupun resistensi klopidogrel tidak berhubungan dengan KKM, terdapat hubungan antara faktor genetik polimorfisme *2 dan *3 gen CYP2C19 dengan KKM.

---

Acute coronary syndrome (ACS) is a national health problem due to high morbidity and mortality, and cost burden as well. Percutaneous coronary intervention (PCI) and antiplatelet therapy such as clopidogrel are recommended. However, ACS patients could still experience major adverse cardiovascular events (MACE). Clopidogrel resistance possibly plays a role in MACE whereas it may be affected by genetic and epigenetic factors. Therefore, the objective of this study was to determine the relationship between genetic factors which are CYP2C19 and P2Y12 polymorphisms, as well as epigenetic factors which are DNA methylation of CYP2C19 and P2Y12, and miRNA-26a expression and their effects on MACE in post-PCI patients.

To analyze the association between genetic and epigenetic factors and clopidogrel resistance, the study design was cross-sectional, while the study design of relationship between genetic and epigenetic factors and MACE was prospective cohort. The subjects were 201 post-PCI ACS patients who received clopidogrel therapy at Harapan Kita Hospital from September 2018 to June 2020. Clopidogrel resistance was determined by light transmission aggregometry (LTA) if the result was greater than 59% with agonist ADP 20 µM. The detection of CYP2C19 and P2Y12 gene polymorphisms and miRNA-26a expression were carried out by qRT-PCR method, while the DNA methylation of the CYP2C19 and P2Y12 genes were carried out by bisulfite conversion method. Patients were observed for one year and angina pectoris, recurrent acute myocardial infarction (AMI), stroke, or death, were recorded as MACE.

From 201 subjects, 45.8% were CYP2C19*2 and CYP2C19*3 polymorphism mutant carrier, 36.8% were rs3679479 P2Y12 polymorphism mutant carrier, 10% were hypomethylated of P2Y12, 80.1% were hypomethylated of CYP2C19, and 66.2% were up regulated in miRNA-26a expression. 49.8% of subjects were clopidogrel resistant and 14.9% of subjects experienced MACE (death was 7.5%). Smoking (p = 0.001; OR 0.37 [CI 95%; 0.20–0.68]), hypomethylated of CYP2C19 (p = 0.037; OR 2.13 [CI 95%; 1.04–4.37]), and up regulated miRNA-26a expression (p = 0.020; OR 2.03 [CI 95%; 1.12–3.68]) were associated with clopidogrel resistance. Female gender (p = 0.040; HR 2.73 [CI 95%; 1.05–7.14]), age over 60 years old (p = 0.035; HR 2.17 [CI 95%; 1.06–4.48]), low eGFR (p = 0.001; HR 3.29 [CI 95%; 1.59–6.84]), and CYP2C19*2 and CYP2C19*3 polymorphisms (p = 0.047; HR 2.12 [CI 95%; 1.01–4.46]) were associated with MACE in one year.

Only DNA methylation of CYP2C19 and miRNA-26a expression were associated with clopidogrel resistance. Although clopidogrel resistance was not associated with MACE, there was association between CYP2C19*2 and CYP2C19*3 polymorphisms and MACE."